Trazodone is a medication used to treat major depressive disorder (MDD). It is in the serotonin-antagonistand-reuptake-inhibitor class of medications with anti-cholinergic effects. Trazodone is known for its sedative effects and is hence often prescribed in those with MDD with concurrent insomnia. While few, there have been reports of patients overdosing on trazodone and developing QTc prolongation leading to fatal arrhythmias such as torsades des pointes and variable atrioventricular blocks. We present a case of a 45year-old female with a past medical history of MDD and anxiety, who presented with dizziness, transient ataxia, and urinary incontinence following ingestion of five 100 mg trazodone tablets. Although her vitals were initially stable on admission, her EKG was concerning for QTc prolongation of 502 ms. A few hours later, she started developing hypotension and progressive QTc prolongation, with a peak of 586 ms. Given the high risk of decompensation, the patient was admitted to the ICU for further care where she received adequate supportive management in the form of fluid resuscitation, electrolyte repletion, serial EKGs every hour, and telemetry monitoring for arrhythmias, with eventual improvement in her clinical condition. Trazodone poisoning, while rare, can be fatal and hence requires close monitoring to prevent complications. Clinicians must be aware of these possible adverse outcomes when managing trazodone toxicity.